Trial
NCT03819660
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
Phase IITERMINATEDREGULATORYConfidence: MEDIUM
Sponsor
Catalyst Pharmaceuticals, Inc.
Collaborators
—
Condition
Spinal Muscular Atrophy Type 3
Intervention
Amifampridine Phosphate 10 MG Oral Tablet
Why stopped
Development of indication not being pursued
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-30